CRH Stock Analysis: CRH | NYSE
Building Materials | NYSE, USA | Market Cap: 63.071m USD | 12M Return: -14.6% | IE0001827041 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 482M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
CRH plc is a Dublin-based building materials company founded in 1936, operating across Ireland, the United States, the United Kingdom, and the broader European market. The business is organized into three segments-Americas Materials Solutions, Americas Building Solutions, and International Solutions-covering a vertically integrated range of products and services from raw materials to finished building components.
The company supplies aggregates, cementitious materials, ready-mixed concrete, asphalt, and precast/prestressed concrete products such as vaults, pipes, and manholes. It also manufactures hardscape and related building products and delivers infrastructure solutions for water, energy, transportation, and telecommunications projects, serving both public infrastructure and private construction end markets.
As a major player in the construction materials sector, CRH benefits from exposure to long-cycle demand drivers such as infrastructure investment, residential construction, and utility network expansion. Aggregates and cement tend to be heavy, low value-to-weight commodities, meaning the industrys economics are heavily shaped by proximity of reserves to end markets and logistical efficiency-factors that have driven the sectors wave of consolidation in recent decades.
- US infrastructure spending boosts aggregates and cement demand
- Housing slowdown pressures Americas Building Solutions volumes
- Energy and input costs squeeze cement margins
| Net Income: 3.40b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.31 > 1.0 |
| NWC/Revenue: 12.29% < 20% (prev 14.24%; Δ -1.96% < -1%) |
| CFO/TA 0.08 > 3% & CFO 5.19b > Net Income 3.40b |
| Net Debt (18.4b) to EBITDA (8.62b): 2.14 < 3 |
| Current Ratio: 1.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (666.9m) vs 12m ago -1.27% < -2% |
| Gross Margin: 34.88% > 18% (prev 36.13%; Δ -1.25% > 0.5%) |
| Asset Turnover: 77.30% > 50% (prev 63.05%; Δ 14.25% > 0%) |
| Interest Coverage Ratio: 6.80 > 6 (EBIT TTM 5.79b / Interest Expense TTM 852.0m) |
| A: 0.09 (Total Current Assets 18.1b - Total Current Liabilities 12.4b) / Total Assets 61.3b |
| B: 0.43 (Retained Earnings 26.6b / Total Assets 61.3b) |
| C: 0.10 (EBIT TTM 5.79b / Avg Total Assets 59.9b) |
| D: 0.72 (Book Value of Equity 25.0b / Total Liabilities 34.9b) |
| Altman-Z'' = 3.42 = A |
| DSRI: 0.82 (Receivables 7.14b/6.96b, Revenue 46.3b/36.9b) |
| GMI: 1.04 (GM 36.13% / 34.88%) |
| AQI: 0.97 (AQ_t 0.27 / AQ_t-1 0.28) |
| SGI: 1.26 (Revenue 46.3b / 36.9b) |
| TATA: -0.03 (NI 3.40b - CFO 5.19b) / TA 61.3b) |
| Beneish M = -2.98 (Cap -4..+1) = A |
As of November 14, 2026, the stock is trading at USD 93.16 with a total of 3,427,205 shares traded. Over the past week, the price has changed by -1.33%, over one month by +16.73%, over three months by -3.87% and over the past year by -14.61%.
Current recommended Stop Loss: 89.00 (which is 4.5% or 1.3 ATR below the current price).
CRH has received a consensus analysts rating of 4.65. Therefore, it is recommended to buy CRH.
- StrongBuy: 16
- Buy: 6
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 121.2 | 30.1% |
Market Cap EUR = 57.1b (63.1b USD * 0.90495997667313 USD.EUR)
P/E Trailing = 17.855
P/E Forward = 15.3846
P/S = 1.6189
P/B = 2.5233
P/EG = 1.6357
Revenue TTM = 46.3b EUR
EBIT TTM = 5.79b EUR
EBITDA TTM = 8.62b EUR
Long Term Debt = 14.8b EUR (from longTermDebt, last quarter)
Short Term Debt = 5.20b EUR (from shortTermDebt, last quarter)
Debt = 23.5b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.96b
Net Debt = 18.4b EUR (calculated: Debt 23.5b - CCE 5.11b)
Enterprise Value = 75.5b EUR (57.1b + Debt 23.5b - CCE 5.11b)
Interest Coverage Ratio = 6.80 (Ebit TTM 5.79b / Interest Expense TTM 852.0m)
EV/FCF = 29.73x (Enterprise Value 75.5b / FCF TTM 2.54b)
FCF Yield = 3.36% (FCF TTM 2.54b / Enterprise Value 75.5b)
FCF Margin = 5.48% (FCF TTM 2.54b / Revenue TTM 46.3b)
Net Margin = 7.35% (Net Income TTM 3.40b / Revenue TTM 46.3b)
Gross Margin = 34.88% ((Revenue TTM 46.3b - Cost of Revenue TTM 30.2b) / Revenue TTM)
Gross Margin QoQ = 34.46% (prev 39.84%)
Tobins Q-Ratio = 1.23 (Enterprise Value 75.5b / Total Assets 61.3b)
Interest Expense / Debt = 3.62% (Interest Expense 852.0m / Debt 23.5b)
Taxrate = 27.67% (1.29b / 4.67b)
NOPAT = 4.19b (EBIT 5.79b * (1 - 27.67%))
Current Ratio = 1.46 (Total Current Assets 18.1b / Total Current Liabilities 12.4b)
Debt / Equity = 0.94 (Debt 23.5b / totalStockholderEquity, last quarter 25.0b)
Debt / EBITDA = 2.14 (Net Debt 18.4b / EBITDA 8.62b)
Debt / FCF = 7.26 (Net Debt 18.4b / FCF TTM 2.54b)
Total Stockholder Equity = 24.0b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.68% (Net Income 3.40b / Total Assets 61.3b)
RoE = 14.17% (Net Income TTM 3.40b / Total Stockholder Equity 24.0b)
RoCE = 14.92% (EBIT 5.79b / Capital Employed (Equity 24.0b + L.T.Debt 14.8b))
RoIC = 8.08% (NOPAT 4.19b / Invested Capital 51.8b)
WACC = 7.44% (E(57.1b)/V(80.6b) * Re(9.43%) + D(23.5b)/V(80.6b) * Rd(3.62%) * (1-Tc(0.28)))
Discount Rate = 9.43% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.89 | Cagr: -1.43%
[DCF] Terminal Value 75.10% ; FCFF base≈2.57b ; Y1≈2.52b ; Y5≈2.56b
[DCF] Fair Price = 32.48 (EV 40.0b - Net Debt 18.4b = Equity 21.6b / Shares 665.2m; r=8.35% [WACC [floored]]; 5y FCF grow -2.50% → 2.50% )
EPS Correlation: 97.60 | EPS CAGR: 11.29% | SUE: -0.36 | # QB: 0
Revenue Correlation: -49.90 | Revenue CAGR: -7.30% | SUE: 4.0 | # QB: 1
EPS current Quarter (2027-03-31): EPS=-0.29 | Chg30d=-71.43% | Revisions=-50% | Analysts=5
EPS current Year (2026-12-31): EPS=5.35 | Chg30d=-7.19% | Revisions=-55% | GrowthEPS=-4.8% | GrowthRev=+5.5%
EPS next Year (2027-12-31): EPS=6.04 | Chg30d=-4.56% | Revisions=-62% | GrowthEPS=+21.7% | GrowthRev=+9.3%
[Analyst] Revisions Ratio: -71% (up=2, down=19)